Northwire Canada EditionThursday, October 15, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4% GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4%
Financings Routine +

Medicenna Announces Closing of Public Offering of Units Raising CDN$4.44 Million to Support Lead Programs

Medicenna Secures $12.4M Lifeline Amidst Dilution Concerns and Clinical Milestones

By The Northwire Desk — AI Analysis May 28, 2026 · 09:10 MDNA · 0.425 MEDICENNA THERAPEUTICS CORP. J
Executive Summary
  • Medicenna Therapeutics Corp. announced the closing of a public offering raising CDN$4.44 million via 8,880,000 Units at CDN$0.50 per Unit.
  • Each unit includes one common share and one-half of one warrant (exercise price $0.65, expiry 3 years).
  • A separate structured financing agreement was entered into with Sorbie Bornholm LP and Sorbie Investments LLP for CDN$8.0 million.
  • The company issued compensation warrants to the sole agent, Bloom Burton Securities Inc., totaling 450,100 units (exercise price $0.50, expiry 2 years).
  • Proceeds are designated for clinical and regulatory development of lead programs MDNA11 and MDNA113, working capital, and general corporate purposes.
  • This closing follows the May 22, 2026 announcement of the prospectus supplement and investment term sheet which outlined these same terms.
Material Impact
  • The financing provides critical liquidity to extend cash runway beyond the previously stated mid-2026 limit, reducing immediate bankruptcy risk.
  • However, the dilution is significant: approximately 8.88 million new shares plus warrants from the public offering and Sorbie investment (16 million units).
  • The equity swap "Sharing Agreement" with Sorbie introduces volatility; proceeds are settled via 18 monthly tranches based on share performance against a benchmark price, creating potential future cash flow uncertainty or additional dilution if stock underperforms.
  • The market reaction to the announcement of terms (May 22) was negative, evidenced by the price drop from $0.66 (May 19) to $0.43 (May 27), suggesting investors priced in the dilutive nature before closing.
  • As a closing event for previously disclosed terms, this is not "genuinely new" information but confirms execution of the capital raise strategy.
MDNA · Price
Company Overview
  • Company: Medicenna Therapeutics Corp., a biopharmaceutical company focused on immunotherapy for cancer.
  • Flagship Project (MDNA11): A long-acting, "beta-enhanced not-alpha" IL-2 Superkine currently in Phase 1b/2 trials (ABILITY-1) and Phase 1b neoadjuvant trial (NEO-CYT).
  • Secondary Asset (MDNA113): First-in-class tumor-anchored anti-PD-1 x IL-2 bifunctional Superkine; preclinical data presented at AACR 2026 showed superior tolerability in non-human primates.
  • Third Asset (Bizaxofusp/MDNA55): IL-4 Empowered Superkine targeting recurrent glioblastoma; Phase 2b trial showed median OS of 13.6 months vs 7 months standard care.
  • Development Stage: MDNA11 is in clinical trials for advanced solid tumors and melanoma; MDNA113 is preclinical awaiting IND filing.
Read the original news release →

More from MEDICENNA THERAPEUTICS CORP. J

Jun 26, 2026 · 08:45

Medicenna Therapeutics Reports Fiscal Year 2026 Financial Results and Operational Highlights

Earnings Jun 11, 2026 · 07:00

Medicenna Strengthens U.S. Patent Estate with Newly Issued and Allowed Patents Across its IL-2, IL-4 and IL-13 Superkine Platforms

M&A / Property Jun 03, 2026 · 07:00

ASCO Presentation Offers No New Catalysts as Dilutive Capital Raise Extends Runway Amid Steep Equity Erosion

Other May 22, 2026 · 07:00

Medicenna Files $13M Financing at Deep Discount as Cash Dwindles and Stock Spirals

Financings May 19, 2026 · 07:00

Financing Finalized at Discount as Dilution Concerns Weigh on Stock

Financings May 13, 2026 · 16:01

Cash Runway Expiry Triggers Dilutive Financing Despite Clinical Milestones

Financings